Table 2.
Efficacy of (PEG-)IFN-free antiviral therapy in patients with HCV-associated decompensated cirrhosis in controlled, prospective trials
| Author | Therapy regime | Treatment duration, weeks | Genotypea | n (all) | n (MELD > 16) | SVR12 (all), n | SVR12 (MELD > 16), n |
|---|---|---|---|---|---|---|---|
| Charlton M, et al. [39]b | LDV/SOF + RBV | 12–24 | 1, 4 | 108d | 27 | 89/108 (82%) | ns |
| Curry MP, et al. [40] | SOF/VELc ± RBV | 12–24 | 1, 2, 3, 4, 6 | 267 | 12 | 234/267 (88%) | ns |
| Manns M, et al. [43]b | LDV/SOF/RBV | 12 | 1, 4 | 140 | 41 | 121/140 (86%) | ns |
| Poordad F, et al. [42]b | LDV/SOF + RBV | 12 (–24) | 1, 2, 3, 4, 6 | 60d | 13 | 50/60 (83%) | ns |
a
Most studies investigated mainly genotype 1.
b
Preliminary results with regard to publication status or completed SVR12.
c
Until November 2015, VEL has not been not approved by the EMA or FDA yet.
d
The complete study included patients prior to and after liver transplantation.
DCV = Daclatasvir; LDV = ledipasvir; RBV = ribavirin; SMV = simeprevir; SOF = sofosbuvir; VEL = velpatasvir; ns = not specified.